TEVA240705P15000
- 0.02
- 0.000.00%
Teva Pharmaceutical Industries Newsroom
Daily short sale tracking: Sirius XM's short volume increased by 5 million, with a short sale ratio of 37%
Sirius XM(SIRI.US) ranked top of the list had the largest change in short volume (5.63 million shares), and the short volume ratio of FirstEnergy(FE.US) reached 37.85%. See more about the top 10 list of short selling volume changes in the latest trading day of the US stock market.
Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 A.m. ET on July 31, 2024
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesda
BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $21
BofA Securities analyst Jason Gerberry maintains $Teva Pharmaceutical Industries(TEVA.US)$ with a buy rating, and maintains the target price at $21.According to TipRanks data, the analyst has a succes
Sector Update: Health Care Stocks Slipping in Afternoon Trading
Health care stocks were declining Monday afternoon, with the NYSE Health Care Index down 0.3% and the Health Care Select Sector SPDR Fund (XLV) shedding 0.6%. The iShares Biotechnology ETF (IBB) fell
Update: Market Chatter: Teva Pharmaceuticals Faces FTC Probe on Patent Listings
(Adds details starting in second paragraph.) Teva Pharmaceutical Industries (TEVA) faces a Federal Trade Commission investigation into the company's alleged refusal to remove two dozen patents for its
Teva Focus of FTC Investigation Over Inhaler Patents
FTC Opens Investigation Into Teva Pharmaceuticals, Washington Post Reports
09:50 AM EDT, 07/01/2024 (MT Newswires) -- FTC Opens Investigation Into Teva Pharmaceuticals, Washington Post Reports Price: 16.23, Change: -0.02, Percent Change: -0.12
Express News | The Federal Trade Commission (FTC) has begun an investigation into pharmaceutical company Teva. (The Washington Post)
Vanda Will Request Relief From Court That Includes Order Requiring Defendants to Discontinue Marketing Generic Versions of HETLIOZ >VNDA
Vanda Will Request Relief From Court That Includes Order Requiring Defendants to Discontinue Marketing Generic Versions of HETLIOZ >VNDA
Vanda Intends to Proceed With Discovery in the Case to Continue Pursuing Its Claims >VNDA
Vanda Intends to Proceed With Discovery in the Case to Continue Pursuing Its Claims >VNDA
Vanda: Court Concluded Issues of Patentability Weren't Same as Those Resolved in Prior Patent-Infringement Litigation Between Parties >VNDA
Vanda: Court Concluded Issues of Patentability Weren't Same as Those Resolved in Prior Patent-Infringement Litigation Between Parties >VNDA
Vanda: Court Denied Motions for Judgment on Pleadings That Were Filed by Teva Pharmaceuticals USA and Apotex >VNDA
Vanda: Court Denied Motions for Judgment on Pleadings That Were Filed by Teva Pharmaceuticals USA and Apotex >VNDA
Teva Pharmaceuticals Presents 4th Interim Analysis Of PEARL Migraine Prevention Study At EAN Congress; New Sub-Analysis Highlights Potential Negative Impact Of Treatment Pauses On Patient Outcomes
4th interim analysis of PEARL real world migraine prevention study presented at 10th European Association of Neurology (EAN) congress in HelsinkiNew sub-analysis of PEARL data highlights potential neg
New AJOVY (Fremanezumab) Migraine Prevention Data Challenges Treatment Pauses
4th interim analysis of PEARL real world migraine prevention study presented at 10th European Association of Neurology (EAN) congress in Helsinki New sub-analysis of PEARL data highlights potential
Teva Pharmaceuticals Is Maintained at Buy by Jefferies
Teva Pharmaceuticals Is Maintained at Buy by Jefferies
Jefferies Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $23
Jefferies analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $19 to $23.
Teva Pharmaceutical Indus Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/27/2024 39.56% Jefferies $19 → $23 Maintains Buy 06/05/2024 27.43% Barclays $20 → $21 Maintains Overwei
Jefferies Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $23
Jefferies analyst Glen Santangelo maintains $Teva Pharmaceutical Industries(TEVA.US)$ with a buy rating, and adjusts the target price from $17 to $23.According to TipRanks data, the analyst has a succ
Express News | Teva : Jefferies Raises Target Price to $23 From $19
Express News | Advisory: Alert on Deckers Brands' Unit Teva Was Inadvertently Tagged to Teva Pharmaceutical Industries and Is Being Withdrawn